Skin reactions are side effects of sunitinib therapy with an adverse impact on quality of life often necessitating dose reductions. For conventional antineoplastic agents, such as doxorubicin, previous studies have indicated a possible relationship between sweat excretion and the development of skin toxicity. However, the determination of sunitinib and its active metabolite in sweat has not yet been reported. A sensitive and accurate method for the determination of sunitinib and its active metabolite N-desethylsunitinib in human sweat was developed using highperformance liquid chromatography coupled to tandem mass spectrometry detection (LC-MS-MS). Sweat samples of a patient treated with sunitinib were collected using Pharmchek™ Drugs of Abuse patches to determine cumulative amounts of sunitinib and metabolite. Validation of the LC-MS-MS method was performed over a range from 1.0 to 200 ng/patch with good intra-and interassay accuracies for sunitinib and N-desethylsunitinib. Ranges of 76-119 and 7.9-10.5 ng/patch for cumulative secretion of sunitinib and metabolite, respectively, were found in patient samples. To our knowledge, this is the first method for determination of cumulative secretion of sunitinib and N-desethylsunitinib in human sweat samples. Sunitinib and its metabolite were easily detectable in sweat patches of a patient treated with sunitinib.
Introduction
Sunitinib (Sutent ® ) is an orally available inhibitor of multiple tyrosine kinases. Sunitinib has proven efficacy as single agent in several solid tumor types and is approved for use in advanced renal cell cancer (RCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumors (GISTs) (1, 2) .
Recent findings demonstrated a positive dose-efficacy relationship for sunitinib treatment, indicating that it should be the aim to dose patients as high as possible (3) . Target plasma concentrations of sunitinib plus active metabolite (N-desethylsunitinib) are in the range of 50 to 100 ng/mL, as deduced from pharmacokinetic/pharmacodynamic preclinical data (4) (5) (6) (7) (8) . However, within this target range, some patients still develop severe toxicities.
The most clinically relevant side effect of sunitinib appears to be the development of Hand-Foot Syndrome (HFS). HFS (all grades) occurred in 19% of patients in a pooled analysis of published clinical trials of sunitinib of whom 5% experienced severe HFS (grade 3 or 4) (9, 10) . This skin toxicity severely impacts the quality of life of patients treated with sunitinib and thus impairs activities of daily living. Moreover, it can lead to unavoidable dose modifications or dose interruptions, which can negatively affect treatment efficacy (11, 12) .
The exact pathogenesis of HFS is unknown, but some hypotheses exist concerning the mechanism by which HFS is caused. The primarily affected sites in HFS, the palmoplantar surfaces, have a high density of eccrine glands that continuously excrete sweat (13, 14) . Sweat can contain virtually any substance present in blood (15) . For conventional antineoplastic agents such as doxorubicin, previous studies have indicated a possible relationship between hyperhydrosis on the palms and plantae and the development of skin toxicity (13) . This indicates that sweat functions as a carrier of drug to the skin surface. After excretion on the skin surface, sweat containing the drug may penetrate into the stratum corneum and cause toxicity (13) . However, secretion of sunitinib and its active metabolite N-desethylsunitinib by the eccrine glands in sweat has not yet been studied (11, 12) . Moreover, sweat is a non-conventional biological matrix in bioanalysis, and no methods for determination of sunitinib in sweat have been reported in literature hitherto. We report here the development and validation of a method for determination of sunitinib and its active metabolite (N-desethylsunitinib) in sweat using high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS-MS). Additionally, we report the determination of cumulative excretion of sunitinib and its metabolite in samples from a patient treated with sunitinib.
Materials and Methods

Reagents
The follwoing reference standards and internal standards were provided by the following manufacturers: sunitinib maleate (C 22 Figure 1 . HPLCgrade acetonitrile and methanol were purchased from Biosolve (Valkenswaard, The Netherlands). Distilled water was obtained from B. Braun (Melsungen, Germany). Ammonia 25% was purchased from Merck (Darmstadt, Germany). PharmChek Drugs-of-Abuse patches, used for sweat collection, were from PharmChem (Forth Worth, TX).
Instrumentation
Determination of sunitinib, N-desethylsunitinib, and the internal standard was performed on an HPLC system (LC-20AD Prominence binary solvent delivery system) with a column oven, DGU-20A3 online degasser, and a SIL-HTc controller (Shimadzu, Kyoto, Japan) coupled to a TSQ Quantum Ultra triple-quadrupole MS equipped with an electrospray ionization source (ESI) operating in the positive ion mode (Thermo Fisher Scientific, Waltham, MA). Separation was carried out on a reversed-phase system with a Gemini C 18 column (50 × 2.0-mm i.d., 5.0-µm particle size, Phenomenex, Torrance, CA) protected with a Securityguard Gemini precolumn (4 × 2.0-mm i.d., 5.0-µm particle size, Phenomenex) and thermostatted at 40°C. The injection volume was 10 µL. Compounds were eluted on a linear gradient at a flow rate of 250 µL/min. The mobile phase consisted of a mixture of 10 mM ammonium hydroxide in water at pH 10.5 (A) and 1 mM ammonium hydroxide in methanol (B). Before each new injection the column was reconditioned for 3 min with 55% B (v/v) resulting in a total run time of 10 min. The chromatographic separation conditions are given in Table I . The divert valve was directed to waste during the first 1.5 min and last 2.0 min to prevent the introduction of endogenous compounds into the MS. For quantification, multiple reaction monitoring (MRM) chromatograms were acquired with LCquan™ software version 2.5 (Thermo Fisher Scientific). Positive ions were created at atmospheric pressure, and the quadrupoles were operating in unit resolution (0.7 Da). Mass transitions from m/z 399 to 283 for sunitinib, m/z 371 to 283 for N-desethylsunitinib, and m/z 409 to 283 for internal standard sunitinib-2 H 10 were optimized ( Figure 2 ). The ESI-MS-MS operating parameters used in this study are listed in Table II .
Preparation of calibration and validation samples
A set of stock solutions of sunitinib and N-desethylsunitinib were prepared from two independent weighings: one for the calibration standards and one for the validation samples.
For the preparation of the calibration standards, working solutions in the range from 10 to 1000 ng/mL were used. Four working solutions in the range from 10 to 800 ng/mL were prepared for spiking the validation samples.
For the preparation of all calibration and validation samples, sweat patches (Pharmchek Drugs-of-Abuse patches) applied on the upper arm of healthy volunteers for at least 24 h were used. Halves of these drug-free blank sweat patches were spiked with a volume of working solution to obtain calibration and validation samples with different amounts of sunitinib and Ndesethylsunitinib.
Sample pretreatment
Sample preparation was performed and validated on sweat patches that were cut into two equal parts to allow re-analysis of study samples when necessary. Half of each patch was cut into smaller parts, which were transferred into a 2-mL Eppendorf tube. To each sample, 20 µL internal standard sunitinib-2 H 10 (100 ng/mL) and 1.5 mL of extraction solvent (methanol) were added. Tubes were closed and shaken for 60 min. Then the extraction solvent was transferred into an Eppendorf tube using a pipette and evaporated under a gentle flux of nitrogen at 40°C until dry. To reconstitute the dry extracts, 100 µL of a mixture of eluent A and eluent B (1:1, v/v) was used. The samples were homogenized by vortex mixing for 30 s. In order to eliminate any present sweat patch fibers, the final extract was centrifuged at 3000 × g for 1 min at room temperature. The supernatant was transferred into an autosampler vial, and 10 µL was injected onto the HPLC column.
Validation experiments
A validation of the assay was performed according to the FDA guidelines for validation of bioanalytical assays including linearity, inaccuracy, precision, specificity, selectivity, cross-analyte/internal standard interference, recovery, ion suppression, carryover, and stability (16, 17) . Because blank human sweat is difficult to obtain, procedures for assessment of recovery, ion suppression, and stability were performed on just one concentration level of the calibration range.
Calibration curves. Six non-zero calibration samples were prepared by fortifying sweat patches with working solutions. The final concentrations were 0.00, 1.00, 5.00, 10.0, 50.0, 100, and 200 ng/patch of sunitinib and N-desethylsunitinib. The lowest calibration sample (1.00 ng/mL) is defined as the lower limit of quantification (LLOQ) and the highest calibration sample (200 ng/mL) is defined as the upper limit of quantification (ULOQ). Calibration samples were analyzed in duplicate in three separate analytical runs. The linear regression of the area ratio of the analytes and the internal standard peaks versus the concentration were weighted with weighting factor 1/x 2 . The linearity was evaluated by means of back-calculated concentrations of the calibration standards.
Inaccuracy and precision. Inaccuracy and precision of the assay were established by analyzing validation samples with analyte concentrations at the LLOQ and at low, mid, and high concentration of the calibration range. The final concentrations were 1.00, 3.00, 20.0, and 160 ng/patch for both analytes.
Replicates of each validation sample were measured in three separate analytical runs to evaluate the intra-and interassay inaccuracy and precision. Validation samples with analyte concentrations above the ULOQ were processed and diluted 1:10 (v/v) in reconstitution solvent before injection to obtain analyte single reaction monitoring (SRM) responses within the validated range. These samples were processed in fivefold and measured in a single analytical run with a dilution factor of 1:10 on the internal standard concentration to assess the inaccuracy and precision after dilution. For acceptance, the intra-and interassay inaccuracies should be within ±20% for the LLOQ and ±15% for all other concentrations. The precisions CV% should be less than 20% for the LLOQ and less than 15% for all other concentrations. Specificity and selectivity. To investigate whether endogenous compounds from sweat could interfere with the detection of the analytes or the internal standard, six different batches of control drug-free human sweat patches were prepared as double blanks (containing neither analyte nor internal standard) and LLOQ samples. Areas of peaks co-eluting with the analytes should not exceed 20% of the area at the LLOQ level and 5% of the area at the internal standard level.
Cross-analyte interference. To investigate possible cross-interference between sunitinib, N-desethylsunitinib, and the internal standard, a cross-interference check was performed. Drug-free human sweat was spiked at ULOQ level (with both analytes separately) and was processed without internal standard. Also, drug-free human sweat with only internal standard was processed. The response of any interfering peak with the same retention time as sunitinib or N-desethylsunitinib should be less than 20% of the response of an LLOQ sample. Matrix effect. Ion suppression was examined by comparing the analytical response of processed blanks spiked with analyte with those of unprocessed samples in reconstitution solvent. Additionally, the matrix factor was calculated by comparing the internal standard corrected analytical response of processed blanks spiked with analyte with those of unprocessed samples in reconstitution solvent.
Recovery. The extraction recovery of the analytes was determined by comparing the analytical response of processed samples with those of processed blanks spiked with analyte.
Carryover. Carryover was tested by injecting two processed blank matrix samples sequentially after injecting an ULOQ sample. The response in the first blank matrix at the retention times of sunitinib, N-desethylsunitinib, and sunitinib-2 H 10 should be less than 20% of the response of an LLOQ sample.
Stability. The stability of sunitinib and N-desethylsunitinib in spiked sweat patches after two freeze/thaw cycles from nominally -20°C to ambient temperatures and after 7 days at ambient temperatures and skin temperature (32°C) was investigated. Additionally, the long-term stability of sunitinib and N-desethylsunitinib in sweat patches stored at -20°C for 14 months was investigated. The processed sample stability of sunitinib and N-desethylsunitinib was investigated after 1 day (ambient temperature) and 7 days (2-8°C). The re-injection reproducibility was determined after 7 days of storage in the autosampler (4°C). The analytes were considered to be stable in the matrix or final extract if 85-115% of the initial concentrations was recovered.
Patient samples. A 68-year-old female patient was treated with sunitinib for metastasized renal cell cancer (mRCC). The sunitinib regimen consisted of an on-treatment phase of 4 weeks (days 1-28) followed by an off-treatment phase of 2 weeks (days 29-42). She received a modified dosing scheme with reduced doses (alternating 25 mg on one day and 37.5 mg the other days), but she suffered from HFS nevertheless. To collect sweat samples, sweat patches were applied to the patients upper arm during seven consecutive days of the on-treatment phase (days 22-28) and of the off-treatment phase (days 36-42) (see Figure 3) . The patches were stored in accessory plastic bags at -20°C until analysis.
Results and Discussion
Method development
The amount of sunitinib and metabolite in sweat was unknown but expected to be low. However, because it was decided to collect the cumulative amount and not the instantaneous concentration of the drug in sweat for a better reflection of the total skin exposure, assay sensitivity would not be a problem. Sweat samples were collected in a cumulative way by application of the PharmChek Drugs of Abuse patches for seven consecutive days. These sweat patches consist of a cellulose absorption pad of 480 × 320 mm covered with an adhesive semi-permeable polyurethane film layer. Non-volatile substances from sweat will accumulate in the pad. The semi-permeable film layer allows water, oxide, and carbondioxide to pass through the patch keeping the skin underneath healthy and preventing external contamination during the period of application (18) . The sample pre-treatment procedure for sweat patches was derived from previously reported HPLC-MS-MS analyses of the drugs fentanyl and methylphenidate in sweat patches (19, 20) .
During assay development different sample pre-treatment procedures reported in literature were compared (19, 20) : 4.0, 2.0, and 1.5 mL methanol and 1.5 mL methanol/water (1:1 v/v) as extraction solvent; evaporation of the extract in one versus two steps; and using half patches versus cutting the half patches into smaller parts before extraction. The procedure with the highest SRM responses in combination with a good reproducibility was the method using half patches cut into smaller parts before extraction; extraction with 1.5 mL methanol in 2.0-mL Eppendorf tubes; and evaporation of the extract in one step. Before injection of the reconstituted sweat extract onto the column, an additional centrifugation step was inserted to eliminate any sweat patch fibers present, which could possibly clog the HPLC system after sample injection.
Early in the assay development process it became clear that unused patches spiked with analytes gave higher SRM responses than patches worn by healthy volunteers before spiking with analytes. No stable isotope labeled N-desethylsunitinib was available to correct for this apparent ion suppression due to matrix effects during the HPLC-MS-MS analysis. For this reason only sweat patches applied on the upper arm of healthy volunteers for at least 24 h were used for the preparation of calibration and validation samples to take into account any of the matrix effects of sweat and any background signal of the patches. Influence of using batches sweat of different individuals was negligible as established in the selectivity experiments during assay validation.
One half of each patch was used to perform the analysis allowing to perform once a re-analysis on the remaining other half of the patch, when necessary. Sunitinib and N-desethylsunitinib seemed to be homogeneously distributed through the whole patch because the analysis of two halves of one patch showed a low variability in result of CV% 4.78 and 6.44 for sunitinib and N-desethylsunitinib, respectively. Therefore, the use of half a patch was accurate and precise. Moreover, use of half patches did not affect the height of the LLOQ level, because even when using half patches the signal-to-noise ratio (S/N ratio) at LLOQ level (1.0 ng/patch) was >100.
Peaks with satisfactory peak shapes were obtained when the linear gradient starting on 55% eluent B was followed by an isocratic elution with 80% eluent B at a flow rate of 0.25 mL per min (see Table I ). Typical chromatograms of LLOQ samples are depicted in Figure 4 .
In the chromatograms of sunitinib, N-desethylsunitinib, and sunitinib-2 H 10 two peaks with the same molecular mass/mass transition were present. This is due to the presence of E/Z configurations in solution, as has been reported before (21) (22) (23) . The isomerization reaction of the Z-isomer into the E-isomer is induced by exposure to light and is reversible. The retention times of sunitinib were 3.6 and 4.6 min for the E-and Z-isomers, respectively. For the E-and Z-isomers of N-desethylsunitinib the retention times were 3.2 and 4.8 min, respectively. Because both isomers showed equal MS responses, the sum of the SRM responses of both separated isomers of the analytes and internal standard were used to process the data (21) .
Validation experiments
Linearity. The assay was linear over the validated concentration range from 1.00 to 200 ng/patch of sunitinib and N-desethylsunitinib in human sweat. Correlation coefficients (r 2 ) were, respectively, at least 0.991 and 0.989 for sunitinib and Ndesethylsunitinib.
Inaccuracy and precision. The intra-and interassay performance data are presented in Table III .
Selectivity. In MRM chromatograms of six batches of control drug-free human sweat, no interference of endogenous compounds from sweat could be detected with the analyte or the internal standard.
Cross-analyte interference. For sunitinib and the internal standard, no cross-interferences were found. In contrast, when a sample with sunitinib at ULOQ level was processed without internal standard, peaks were detected at the retention time of N-desethylsunitinib. Additionally, by analyzing academic dilutions of freshly prepared sunitinib stock solution, approximately 1% of the sunitinib area was shown in the mass transition window of N-desethylsunitinib. This signal was proportional to the signal in processed cross-analyte interference samples of sunitinib. Therefore, we conclude that the cross-interference originated from the reference standard of sunitinib and did not arise in the samples during processing. The response of the interfering peak in the N-desethylsunitinib window accounted for at most 7.10% (CV % 4.4) of the total SRM response of N-desethylsunitinib in the calibration and validation samples. Because the contribution of the interfering peaks was within 15% of deviation from the nominal concentrations, the results for cross-interference were found to be acceptable, and no relating problems were expected during quantification of the analytes.
Matrix effect. The matrix effect detected for sunitinib and Ndesethylsunitinib was a suppression of SRM signal of 70.4% and 71.4%, respectively. The observed matrix effect was just partly due to influences of the sweat matrix. Namely, because there was also a discrepancy in SRM signal between final extract of spiked unused patches and spiked unprocessed samples (suppression 30.3 for sunitinib and 18.5% for N-desethylsunitinib), the suppression seems to be partly due to exogenous compounds originating from the patches. For quantification of sunitinib the stable isotope labeled internal standard (sunitinib-2 H 10 ) corrected well for the ion suppression effects (matrix factor 1.04). For quantification of N-desethylsunitinib, the matrix factor was 0.89.
Recovery. For sunitinib, the mean extraction recovery was 90.3% and the mean total recovery was 27.6%, and for N-desethylsunitinib, the mean extraction recovery was 71.5% and the mean total recovery was 21.6%. Because of the matrix effect, the total recovery was very low, but this recovery was reproducible nevertheless (CV% 1.1 for sunitinib and CV% 9.5 for N-desethylsunitinib).
Carryover. No carryover was observed because no interfering peaks were detected in processed blank samples injected after an ULOQ sample, which was due to the use of 100% eluent B after elution of the analytes.
Stability. Sunitinib and N-desethylsunitinib are stable in sweat patches for at least two freeze (-20°C)/thaw cycles and in sweat patches at ambient and skin temperatures (20°C and 32°C, respectively) up to at least seven days. Additionally, the long-term stability of sunitinib and N-desethylsunitinib in sweat patches stored at -20°C is at least 14 months. Besides, sunitinib and N-desethylsunitinib are stable in the final extract at least 24 h at ambient temperature and up to 7 days at nominally 2-8°C. Re-injection reproducibility was established and an analytical run can be re-injected after at least 7 days of storage in the autosampler at 4°C.
Sunitinib in patients' sweat samples
The exposure of drugs to the skin during a certain period of time depends on both the concentration of drugs in sweat and the degree of sweat secretion. Moreover, a patient with a low sunitinib concentration in sweat, but a excessively high sweat excretion would have a higher skin exposure than a patient with a high sunitinib concentration in sweat and practically no sweat excretion. Therefore, the cumulative amount of sunitinib in the patch would probably be of more clinical relevance than the absolute concentration of sunitinib in sweat. Thus, it was decided to collect sweat in a cumulative way by application of the sweat patches for seven consecutive days.
As a proof of concept, half a sweat patch from a patient was processed simultaneously with an unused blank patch. This gave satisfying results, because sunitinib and N-desethylsunitinib were easily detectable in the sweat patch which was applied on the upper arm during seven consecutive days. Typical chromatograms of a patient's sweat patch applied during the off-treatment phase (days 36-42) of therapy are depicted in Figure 5 .
In the samples of a patient that were collected during the ontreatment phase and the off-treatment phase of the sunitinib therapy regimen, we found ranges of 76-119 and 7.9-10.5 ng/patch for cumulative secretion of sunitinib and its metabolite, respectively ( Figure 6 ). These amounts were all within the validated range of 1.0 to 200 ng/patch. Additionally, even in the second week after the administration of sunitinib, the cumulative amounts of sunitinib and N-desethylsunitinib in the sweat patches were far above the LLOQ.
At LLOQ level (1.0 ng/patch) an S/N ratio of > 100 was obtained. Because this S/N ratio is high, quantification of amounts less than 1 ng/patch of sunitinib and metabolite would be possible, but these amounts were not found to be clinically relevant. Our patient samples showed cumulative amounts of sunitinib and N-desethylsunitinib above the LLOQ even at the end of the off-treatment phase. As expected, the skin exposure to sunitinib and metabolite during the off-treatment phase is lower compared to the on-treatment phase. In plasma, N-desethylsunitinib levels are approximately one-third of the sunitinib levels (24) . Besides, the secretion onto the skin would be decreased compared to the parent drug because of the more hydrophilic properties of the N-desethyl metabolite (15) , and the observed difference in sunitinib and N-desethylsunitinib levels in sweat during treatment can thereby be explained. Strikingly, in the off-treatment phase of our case, the cumulative levels of the metabolite were higher compared to the parent drug. This observation can be explained by the difference in elimination half life of both compounds, namely 40-60 h for sunitinib and 80-110 h for N-desethylsunitinib. As a result, the metabolite remains in plasma for a longer time period and therefore the excretion of this compound in sweat will also be sustained.
Conclusions
We have developed and validated a sensitive and easy to perform HPLC-MS-MS method for analysis of sunitinib and N-desethylsunitinib in human sweat samples. To our knowledge, this is the first report of bioanalytical determination of sunitinib secretion in sweat of a patient. Human sweat samples are collected using PharmChek Drugs-of-Abuse Patches. The sweat patches with sunitinib and N-desethylsunitinib are pretreated by extraction with methanol and addition of internal standard sunitinib-2 H 10 . A linear dynamic range from 1.0 to 200 ng/patch has been validated. Validation results show that the method is accurate and precise. From our patient samples, we concluded that cumulative amounts of sunitinib and N-desethylsunitinib could be easily detected in human sweat patches applied to the upper arm of a patient over seven consecutive days. 
